In Vitro Diagnostics Market Research Reports & Industry Analysis

The publications below represent comprehensive market research on components of the global market for in vitro diagnostics. Reports, published by several different research companies, address financial analyses of major companies, overview analyses of the global market, and specific analyses on individual countries or individual and more specific segments of the market, such as cell analysis.
...Show More ...Show Less


In Vitro Diagnostics Industry Research & Market Reports

  • Hemostasis Diagnostics

    ... CAGR of 4.8% over the analysis period 2024-2030. Prothrombin Test Time (PT), one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$1.3 Billion by the end of ... Read More

  • Breath Analyzers

    ... CAGR of 15.4% over the analysis period 2024-2030. Fuel Cells Technology, one of the segments analyzed in the report, is expected to record a 16.3% CAGR and reach US$2.6 Billion by the end of the ... Read More

  • Zika Virus Testing

    ... at a CAGR of 5.8% over the analysis period 2024-2030. Molecular Testing, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$192.4 Million by the end of ... Read More

  • Coagulation Factor Concentrates

    ... at a CAGR of 7.2% over the analysis period 2024-2030. Hospitals & Clinics End-Use, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$8.8 Billion by the ... Read More

  • Rapid Medical Diagnostic Kits

    ... 2030, growing at a CAGR of 3.6% over the analysis period 2024-2030. Over the Counter (OTC) Kits, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$10.7 ... Read More

  • Flow Chemistry

    ... CAGR of 8.8% over the analysis period 2024-2030. CSTR, one of the segments analyzed in the report, is expected to record a 8.9% CAGR and reach US$1.1 Billion by the end of the analysis period. ... Read More

  • Drug Abuse Testing

    ... at a CAGR of 5.3% over the analysis period 2024-2030. Laboratory Services, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$52.0 Billion by the end of ... Read More

  • Heparin

    ... 2.8% over the analysis period 2024-2030. Low Molecular Weight Heparin (LMWH), one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$5.9 Billion by the end of the ... Read More

  • High-Density Multiplexed Diagnostic Assays

    ... 2030, growing at a CAGR of 14.7% over the analysis period 2024-2030. Diagnostic Laboratories End-Use, one of the segments analyzed in the report, is expected to record a 15.1% CAGR and reach US$1.8 Billion by ... Read More

  • Industrial Microbiology

    ... CAGR of 4.6% over the analysis period 2024-2030. Pharmaceuticals End-Use, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$11.6 Billion by the end of the analysis ... Read More

  • Leukapheresis

    ... 7.0% over the analysis period 2024-2030. Leukapheresis Devices, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$122.6 Million by the end of the analysis period. Growth ... Read More

  • Life Science Instrumentation

    ... at a CAGR of 4.6% over the analysis period 2024-2030. Spectroscopy Technology, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$24.4 Billion by the end of ... Read More

  • Plasma Fractionation

    ... CAGR of 5.1% over the analysis period 2024-2030. Immunoglobulins, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$14.8 Billion by the end of the analysis period. ... Read More

  • Pneumonia Testing

    ... CAGR of 6.2% over the analysis period 2024-2030. Immunodiagnostics, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$339.9 Million by the end of the analysis period. ... Read More

  • In Vitro Toxicology Testing

    ... 2030, growing at a CAGR of 8.8% over the analysis period 2024-2030. Cell Culture Technology, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$11.2 Billion by ... Read More

  • Hemoglobin Testing

    ... CAGR of 5.6% over the analysis period 2024-2030. Hemoglobin Testing Reagents & Consumables, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$3.0 Billion by the end ... Read More

  • Histology and Cytology

    ... at a CAGR of 14.4% over the analysis period 2024-2030. Cytology, one of the segments analyzed in the report, is expected to record a 15.3% CAGR and reach US$50.6 Billion by the end of the ... Read More

  • Cervical Dysplasia Diagnostics

    ... at a CAGR of 5.9% over the analysis period 2024-2030. Diagnostic Tests, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$793.8 Million by the end of ... Read More

  • Medical Microbiology Testing Technologies

    ... 2030, growing at a CAGR of 4.1% over the analysis period 2024-2030. Respiratory Diseases Indication, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$1.4 Billion by ... Read More

  • Testing and Analysis Services

    ... 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Elemental Analysis, one of the segments analyzed in the report, is expected to record a 6.4% CAGR and reach US$12.4 Billion by the ... Read More

  • Toxicology Testing Services

    ... at a CAGR of 8.4% over the analysis period 2024-2030. In Vivo Method, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$10.2 Billion by the end ... Read More

  • Immunofluorescence Assays

    ... CAGR of 4.4% over the analysis period 2024-2030. Immunofluorescence Assay Reagents, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$3.8 Billion by the end of the ... Read More

  • Laboratory Automated Incubators

    ... at a CAGR of 4.0% over the analysis period 2024-2030. Pharma & Biotech Companies End-Use, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$399.4 Million by ... Read More

  • Mice Model

    ... CAGR of 5.3% over the analysis period 2024-2030. CRISPR / CAS9 Technology, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$976.7 Million by the end of ... Read More

  • Mycotoxin Testing

    ... CAGR of 5.9% over the analysis period 2024-2030. Spectroscopy- & Chromatography-Based Technology, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$1.6 Billion by the end of ... Read More

Cookie Settings